UB Paderborn / Katalog / Suche / in CDI

Pharmacokinetics of Peptide–Fc Fusion Proteins

Journal of pharmaceutical sciences, 2014-01, Vol.103 (1), p.53-64

2014

Link zum Volltext

Verfügbarkeit prüfen

Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer

Clinical pharmacology and therapeutics, 2024-03, Vol.115 (3), p.468-477

2024

Link zum Volltext

Verfügbarkeit prüfen

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma

Clinical and translational science, 2022-12, Vol.15 (12), p.3000-3011

2022

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis

Journal of clinical pharmacology, 2022-05, Vol.62 (5), p.656-669

2022

Link zum Volltext

Verfügbarkeit prüfen

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

Journal of clinical pharmacology, 2021-05, Vol.61 (5), p.614-627

2021

Link zum Volltext

Verfügbarkeit prüfen

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

The New England journal of medicine, 2008-07, Vol.359 (1), p.31-42

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

Journal of clinical oncology, 2009-08, Vol.27 (23), p.3794-3801

2009

Link zum Volltext

Verfügbarkeit prüfen

AMG 386 in Combination With Sorafenib in Patients With Metastatic Clear Cell Carcinoma of the Kidney: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study

Cancer, 2012-12, Vol.118 (24), p.6152-6161

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Journal of clinical oncology, 2012-02, Vol.30 (4), p.362-371

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

Journal of clinical oncology, 2009-07, Vol.27 (21), p.3557-3565

2009

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2007-06, Vol.25 (17), p.2369-2376

2007

Link zum Volltext

Verfügbarkeit prüfen

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

Clinical rheumatology, 2009-02, Vol.28 (2), p.129-137

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer

Clinical cancer research, 2010-01, Vol.16 (1), p.279-290

2010

Link zum Volltext

Verfügbarkeit prüfen

A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

Journal of clinical pharmacology, 2011-01, Vol.51 (1), p.6-8

2011

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

Arthritis research & therapy, 2011-07, Vol.13 (4), p.R125-R125

2011

Link zum Volltext

Verfügbarkeit prüfen

Transit Compartments versus Gamma Distribution Function To Model Signal Transduction Processes in Pharmacodynamics

Journal of pharmaceutical sciences, 1998-06, Vol.87 (6), p.732-737

1998

Link zum Volltext

Verfügbarkeit prüfen

Wu B, Sun Y-N. 2013. Pharmacokinetics of Peptide–Fc Fusion Proteins. J Pharm Sci 103:53–64

Journal of pharmaceutical sciences, 2014-06, Vol.103 (6), p.1928-1928

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Clinical cancer research, 2010-06, Vol.16 (11), p.3044-3056

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

BMC cancer, 2011-07, Vol.11 (1), p.313-313, Article 313

2011

Link zum Volltext

Verfügbarkeit prüfen

Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma

Targeted oncology, 2022-07, Vol.17 (4), p.433-439

2022

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti-CD11a Antibody) Following Long-Term Subcutaneous Weekly Dosing in Psoriasis Subjects

Journal of clinical pharmacology, 2005-04, Vol.45 (4), p.468-476

2005

Link zum Volltext

Verfügbarkeit prüfen

Investigation of the Mechanism of Clearance of AMG 386, a Selective Angiopoietin-1/2 Neutralizing Peptibody, in Splenectomized, Nephrectomized, and FcRn Knockout Rodent Models

Pharmaceutical research, 2012-04, Vol.29 (4), p.1057-1065

2012

Link zum Volltext

Verfügbarkeit prüfen

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

Advances in therapy, 2020-04, Vol.37 (4), p.1464-1478

2020

Link zum Volltext

Verfügbarkeit prüfen

Investigation of the Pharmacokinetics of Romiplostim in Rodents with a Focus on the Clearance Mechanism

Pharmaceutical research, 2011-08, Vol.28 (8), p.1931-1938

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

Advances in therapy, 2018-11, Vol.35 (11), p.1859-1872

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics of Peptide–Fc Fusion Proteins

Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma

Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

AMG 386 in Combination With Sorafenib in Patients With Metastatic Clear Cell Carcinoma of the Kidney: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer

A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

Transit Compartments versus Gamma Distribution Function To Model Signal Transduction Processes in Pharmacodynamics

Wu B, Sun Y-N. 2013. Pharmacokinetics of Peptide–Fc Fusion Proteins. J Pharm Sci 103:53–64

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma

Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti-CD11a Antibody) Following Long-Term Subcutaneous Weekly Dosing in Psoriasis Subjects

Investigation of the Mechanism of Clearance of AMG 386, a Selective Angiopoietin-1/2 Neutralizing Peptibody, in Splenectomized, Nephrectomized, and FcRn Knockout Rodent Models

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

Investigation of the Pharmacokinetics of Romiplostim in Rodents with a Focus on the Clearance Mechanism

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

Suchergebnisse filtern